AbbVie (ABBV) Income towards Parent Company (2012 - 2026)

AbbVie (ABBV) reported Income towards Parent Company of $697.0 million for Q1 2026, down 45.93% year-over-year from $1.3 billion in Q1 2025, and down 61.6% quarter-over-quarter from $1.8 billion in Q4 2025.

AbbVie (ABBV) Income towards Parent Company (2012 - 2026) Analysis & Trends

AbbVie (ABBV) has 15 years of Income towards Parent Company data on file, last reported at $697.0 million in Q1 2026.

  • Income towards Parent Company for Q1 2026 came in at $697.0 million, down 45.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 billion (down 13.37% YoY), and the FY2025 annual result was $4.2 billion, down 1.24% from the prior year.
  • Income towards Parent Company slipped to $697.0 million in Q1 2026 per ABBV's latest filing, from $1.8 billion in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $4.5 billion in Q1 2022 and troughed at -$97.0 million in Q1 2023.
  • A 5-year average of $1.5 billion and a median of $1.4 billion in 2024 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2024 and 2025: Income towards Parent Company tumbled 102.79% in 2024, then surged 7991.3% in 2025.
  • A 5-year view of Income towards Parent Company shows it stood at $2.5 billion in 2022, then sank by 66.67% to $824.0 million in 2023, then plunged by 102.79% to -$23.0 million in 2024, then surged by 7991.3% to $1.8 billion in 2025, then tumbled by 61.6% to $697.0 million in 2026.
  • Business Quant data shows ABBV's Income towards Parent Company at $697.0 million in Q1 2026, $1.8 billion in Q4 2025, and $188.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 697.00 Mn
Dec 31, 2025 1.82 Bn
Sep 30, 2025 188.00 Mn
Jun 30, 2025 941.00 Mn
Mar 31, 2025 1.29 Bn
Dec 31, 2024 -23.00 Mn
Sep 30, 2024 1.56 Bn
Jun 30, 2024 1.37 Bn
Mar 31, 2024 1.37 Bn
Dec 31, 2023 824.00 Mn
Sep 30, 2023 1.78 Bn
Jun 30, 2023 2.03 Bn
Mar 31, 2023 -97.00 Mn
Dec 31, 2022 2.47 Bn
Sep 30, 2022 3.95 Bn
Jun 30, 2022 928.00 Mn
Mar 31, 2022 4.49 Bn
Dec 31, 2021 4.05 Bn
Sep 30, 2021 3.18 Bn
Jun 30, 2021 744.00 Mn